Idenix Pharmaceuticals (NASDAQ: IDIX) received more bad news today after reporting that the FDA will require more preclinical data before it can proceed with clinical trials for its experimental hepatitis C drug IDX20963. In the following video, health-care analyst Max Macaluso discusses what this news means in the context of Idenix's previous drug development problems.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.